First-Line Treatment of Atopic Dermatitis When Moisturization Is Not Enough
Clinical Scenario
Atopic dermatitis that remains uncontrolled despite moisturization alone warrants the addition of active topical pharmacotherapy. This first-line protocol defines the evidence-based next step in that situation.
Treatment Approach — partial summary only
The protocol involves adding a specific class of topical agent applied once daily, with defined restrictions on which agent types should be avoided on sensitive anatomical sites or over prolonged treatment durations.
Expected Response
Improvement of atopic dermatitis is typically expected within 2 to 6 weeks of initiating therapy.
References
DOI: 10.1016/j.anai.2023.11.009
- In patients with uncontrolled atopic dermatitis refractory to moisturization alone, the JTF panel recommends addition of a topical corticosteroid over no topical corticosteroid (strong recommendation, high-certainty evidence).
- In patients aged 3 months or older with uncontrolled atopic dermatitis refractory to moisturization alone, the JTF panel recommends addition of a topical calcineurin inhibitor (pimecrolimus, tacrolimus) over no added topical calcineurin inhibitor (strong recommendation, high-certainty evidence).
- In patients with uncontrolled atopic dermatitis using mid-to high-potency topical treatments (tacrolimus, topical corticosteroid US classes 1-5), the JTF panel suggests applying the medication once per day over twice per day (conditional recommendation, moderate certainty evidence).
- Avoid high-potency (classes 1 and 2) TCS for prolonged periods of time (>4 weeks) and limit its use on sensitive areas (face, folds, groin)—rare instances of atrophy, telangiectasia, and striae may be more likely to occur in these areas.
- The available RCTs systematically reviewed (topical and systemic NMAs) and AD experts typically expect response to mid- or high-potency topical therapy within 2 to 6 weeks.
View source ↗